HEK293 N SARS-CoV-2 Nucleocapsid Overexpression Stable Cell Line

Product Description

Safely study the SARS-CoV-2 nucleocapsid protein with our ready-to-use HEK293 "N" SARS-CoV-2 Nucleocapsid Overexpression Stable Cell Line. 

• Leverage SBI’s robust lentivector expression technology to study the ACE2 receptor
• Ready-to-use stable cell line accelerates your SARS-CoV-2 studies
• Lentivector is also available as plasmid and pre-packaged virus

Explore interactions of the SARS-CoV-2 nucleocapsid protein with host proteins and more using the HEK293 "N" SARS-CoV-2 Nucleocapsid Overexpression Stable Cell Line. Built using the SARS-CoV-2 Nucleocapsid (N protein) Expression Lentivector, this stable cell line overexpresses the SARS-CoV-2 "N" protein—the nucleocapsid—from the CMV promoter, with a separate EF1α promoter driving expression of the puromycin resistance gene for selection.

Figure 1. The SARS-CoV-2 nucleocapsid protein is well expressed in the HEK293 "N" SARS-CoV-2 Nucleocapsid Overexpression Stable Cell Line. The SARS-CoV-2 Nucleocapsid Overexpression Lentivector (pCDH-CMV-SARS-CoV-2-N-EF1α-Puro) was transduced into HEK293 cells to create the stable cell line. To demonstrate the robust expression of the nucleocapsid protein in this cell line, total protein was extracted and nucleocapsid protein expression analyzed via western blot. The parental HEK293 cells display no nucleocapsid expression whereas the HEK293 "N" SARS-CoV-2 Nucleocapsid Overexpression Stable Cell Line possesses robust nucleocapsid expression.